Vitamin D and Vitamin D receptor activators in treatment of hypertension and cardiovascular disease

Cardiovascular and Hematological Disorders - Drug Targets

Volumn 14, Issue 1, 2014, Pages 34-44

  Franczyk, Agata ^a   Stolarz Skrzypek, Katarzyna ^a   Wesołowska, Anna ^a   Czarnecka, Danuta ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Cardiovascular system; Hypertension; Vitamin D; Vitamin D analogues; Vitamin D receptor; Vitamin D receptor activators; Vitamin D supplementation

Indexed keywords

22 OXACALCITRIOL; ALFACALCIDOL; ATRIAL NATRIURETIC FACTOR; BISPHOSPHONIC ACID DERIVATIVE; CALCITRIOL; CELL NUCLEUS RECEPTOR; COLECALCIFEROL; DOXERCALCIFEROL; ERGOCALCIFEROL; MEMBRANE RECEPTOR; PARICALCITOL; RENIN; VITAMIN D; VITAMIN D RECEPTOR; CALCITRIOL RECEPTOR;

ADRENERGIC SYSTEM; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); FIBRINOLYSIS; GENE; HEART MUSCLE CELL; HUMAN; HYPERTENSION; IMMUNOMODULATION; INFLAMMATION; NONHUMAN; OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; THROMBOSIS; VASCULARIZATION; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; CARDIOVASCULAR DISEASES; METABOLISM;

ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; HYPERTENSION; RECEPTORS, CALCITRIOL; VITAMIN D;

EID: 84905647421     PISSN: 1871529X     EISSN: None     Source Type: Journal    
DOI: 10.2174/1871529X14666140228122836     Document Type: Article

References (96)

1. Boonen, S.; Bischoff-Ferrari, H.A.; Cooper, C.; Lips, P.; Ljunggren, O.; Meunier, P.J.; Reginster, J.Y. Addressing the musculoskeletal components of fracture risk with calcium and vitamin D: a review of the evidence. Calcif. Tissue Int., 2006, 78, 257-270.
2. Holick, M.F. Resurrection of vitamin D deficiency and rickets. J. Clin. Invest., 2006, 116, 2062-2072.
3. Pike, J.W. Vitamin D3 receptors: structure and function in transcription. Annu. Rev. Nutr., 1991, 11, 189-216.
4. Zittermann, A. Vitamin D and disease prevention with special reference to cardiovascular disease. Prog. Biophys. Mol. Biol., 2006, 92, 39-48.
5. Dawson-Hughes, B.; Heaney, R.P.; Holick, M.F.; Lips, P.; Meunier, P.J.; Vieth, R. Estimates of optimal vitamin D status. Osteoporos. Int., 2005, 16, 713-716.
6. Dusso, A.S.; Brown A.J.; Slatopolsky E. Vitamin D. Am. J. Physiol. Renal. Physiol., 2005, 289, F8-F28.
7. Holick, M.F. Vitamin D: a millenium perspective. J. Cell Biochem., 2003, 88, 296-307.
8. Chen, T.C.; Chimeh, F.; Lu, Z.; Mathieu, J.; Person, K.S.; Zhang, A.; Kohn, N.; Martinello, S.; Berkowitz, R.; Holick, M.F. Factorsthat influence the cutaneous synthesis and dietary sources of vitamin D. Arch. Biochem. Biophys., 2007, 460, 213-217.
9. Jones, G. Expanding role for vitamin D in chronic kidney disease: importance of blood 25-OH-D levels and extra-renal 1alphahydroxylase in the classical and nonclassical actions of 1alpha,25-dihydroxyvitamin D(3). Semin. Dial., 2007, 20, 316-324.
10. Rochel N.; Wurtz J.M.; Mitschler A.; Klaholz B.; Moras D. The crystal structure of the nuclear receptor for vitamin D bound to its natural ligand. Mol. Cell., 2000, 5, 173-9.
11. Alpert, P.T.; Shaikh U. The effects of vitamin D defi ciency and insuffi ciency on the endocrine and paracrine systems. Biol. Res. Nurs., 2007, 9, 117-129.
12. DeLuca, H.F. Overview of general physiologic features and functions of vitamin D. Am. J. Clin. Nutr., 2004, 80, 1689S-1696S.
13. Galbiati F.; Polastri L.; Thorens B.; Dupraz P.; Fiorina P.; Cavallaro U.; Christofori G.; Davalli A.M. Molecular pathways involved in the antineoplastic effects of calcitriol on insulinoma cells. Endocrinology, 2003, 144, 1832-1841.
14. Marcinkowska, E. A run for a membrane vitamin D receptor. Biol. Signals Recept., 2001, 10, 341-349.
15. Płudowski, P.; Karczmarewicz, E.; Czech-Kowalska, J.; Kryśkiewicz, E.; Skorupa, E.; Dobrzańska, A. Nowe spojrzenie na suplementacje{ogonek} witamina{ogonek} D. Standardy Med., 2009, 1, 23-41.
16. Bai, S.; Favus, M.J. Vitamin D and calcium receptors: links to hypercalciuria. Curr Opin Nephrol Hypertens., 2006, 6, 381-385.
17. Holick, M.F. Phylogenetic and evolutionary aspects of vitamin D from phytoplankton to humans. Vertebrate Endocrinology. Fundamentals and biochemical implications. Academic Press. 1989, 3, 7-43.
18. Holick, M. Vitamin D deficiency. N. Engl. J. Med., 2007, 357, 266-281.
19. Dawson-Hughes, B.; Heaney, R.P.; Holick, M.F.; Lips, P.; Meunier, P.J.; Vieth, R. Estimates of optimal vitamin D status. Osteoporos Int., 2005, 16, 713-716.
20. Norman, A.W. From vitamin D to hormone: fundamentals of the vitamin D endocrine system. Am. J. Clin. Nutr., 2010, 88, 491S-499S.
21. Bouillon, R.; Okamura, W.H.; Norman, A.W. Structure-function relationships in the vitamin D endocrine system. Endocrine Rev., 1995, 16, 200-257.
22. Muindi, J.R.; Peng, Y.; Potter, D.M.; Hershberger, P.A.; Tauch, J.S.; Capozzoli, M.J.; Egorin, M.J.; Johnson, C.S.; Trump, D.L. Pharmacokinetics of high-dose oral calcitriol: results from a phase 1 trial of calcitriol and paclitaxel. Clin. Pharmacol. Ther., 2002, 72, 648-659.
23. Buell, J.S.; Dawson-Hughes, B. Vitamin D and neurocognitive dysfunction: Preventing "D"ecline? Mol. Aspects Med., 2008, 29, 415-422.
24. Grant, W.B. Does vitamin D reduce the risk of dementia? J. Alzheimers Dis., 2009, 17, 151-159.
25. Garattini, E.; Terao, M. Cytodifferentiation: a novel approach to cancer treatment and prevention. Curr. Opin. Pharmacol., 2001, 1, 358-363.
26. Hou M.F.; Tien Y.C.; Lin G.T.; Chen C.J.; Liu C.S.; Lin S.Y.; Huang T.J. Association of vitamin D receptor gene polymorphism with sporadic breast cancer in Taiwanese patients. Breast Cancer Res. Treat., 2002, 74, 1-7.
27. Adorini L. Tolerogenic dendritic cells induced by vitamin D receptor ligands enhance regulatory T cells inhibiting autoimmune diabetes. Ann. NY Acad. Sci., 2003, 987, 258-261.
28. Marcinkowska-Suchowerska, E.; Kozłowska-Wojciechowska, M.; Filipiak, K.J. Suplementacja witaminy D u dorosłych. Terapia, 2010, 1, 3-7.
29. Cantorna, M.T.; Hullett, D.A,; Redaelli, C.; Brandt, C.R.; Humpal-Winter, J.; Sollinger, H.W.; DeLuca, H.F. 1,25-Dihydroxyvitamin D3 prolongs graft survival without compromising host resistance to infection or bone mineral density. Transplantation, 1998, 66, 828-831.
30. Cantorna, M.T.; Woodward, W.D.; Hayes, C.E.; DeLuca, H.F. 1,25 Dihydroxyvitamin D3 is a positive regulator for the two antiencephalitogenic cytokines TGF-b1 and IL-4. J. Immunol., 1998, 160, 5314-5319.
31. Adorini, L. Tolerogenic dendritic cells induced by vitamin D receptor ligands enhance regulatory T cells inhibiting autoimmune diabetes. Ann. NY Acad. Sci., 2003, 987, 258-261.
32. Diaz, G.D.; Paraskeva, C.; Thomas, M.G.; Binderup, L.; Hague, A. Apoptosis is induced by the active metabolite of vitamin D3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: possible implications for prevention and therapy. Cancer Res., 2000, 60, 2304-2312.
33. Zittermann A.; Gummert J.F.; Börgermann J. Vitamin D deficiency and mortality. Curr. Opin. Clin. Nutr. Metab. Care, 2009, 12, 634-639.
34. Głuszko, P. Znaczenie witaminy D dla rokowania sercowonaczyniowego I sprawności osób starszych. Gerontologia Polska, 2010; Vol. 18, 2, 66-70.
35. Anna Dobrzańska; Instytut Pomnik-Centrum Zdrowia Dziecka w Warszawie, Klinika Neonatologii, Patologii i Intensywnej Terapii Noworodka. Polskie zalecenia dotycza{ogonek}ce profilaktyki niedoborów witaminy D, 2009.
36. Swapna, N.; Mohana, Vamsi, U.; Usha, G.; Padma, T. Risk conferred by FokI polymorphism of vitamin D receptor (VDR) gene for essential hypertension. Indian J. Hum. Genet., 2011, 17, 201-206.
37. Czekaj, P. Interakcje receptorów hormonu tarczycy i pochodnych witamin A i D z DNA. Post. Biol. Kom., 1996, 23, 261-278.
38. Jorgensen, H.L.; Scholler, J.; Sand, J.C.; Bjuring, M.; Hassager, C.; Christiansen, C. Relation of common allelic variation at vitamin D receptor locus to bone mineral density and postmenopausal bone mass: Cross sectional and longitudinal population study. Br. Med. J., 1996, 313, 586-590.
39. Hershberger, P.A.; Mcguire, T.F.; Yu, WD.; Zuhowski, E.G.; Schellens, J.H.; Egorin, M.J.; Trump, D.L.; Johnson, C.S. Cisplatin potentiates 1,25-dihydroxyvitamin D3-induced apoptosis in association with increased mitogen-activated protein kinase kinase 1 (MEKK-1) expression. Mol. Cancer Ther., 2002, 1, 821-829.
40. Feldman, D.; Zhao, X.Y.; Krishnan, A.V. Vitamin D and prostate cancer. Endocrinology, 2000, 141, 5-9.
41. Nemere, I.; Schwartz, Z.; Pedrozo, H.; Sylvia, V.L.; Dean, D.D.; Boyan, B.D. Identification of a membrane receptor for 1,25-dihydroxyvitamin D3 which mediates rapid activation of protein kinase C. J. Bone Miner. Res., 1998, 13, 1353-1359.
42. Marcinkowska, E. A run for a membrane vitamin D receptor. Biol Signals Recept., 2001, 10, 341-349.
43. Melamed, M.L.; Michos, E.D.; Post, W.; Astor, B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch. Intern. Med., 2008, 168(15), 1629-37.
44. Wang, L.; Manson, J.E.; Song, Y.; Sesso, H.D.; Systematic review: vitamin D and calcium supplementation in prevention of cardiovascular events. Ann. Intern. Med., 2010, 152(5), 315-23.
45. Avenell, A, MacLennan, G.S.; Jenkinson, D.J.; McPherson, G.C.; McDonald, A.M.; Pant, P.R.; Grant, A.M.; Campbell, M.K.; Anderson, F.H.; Cooper, C.; Francis, R.M.; Gillespie, W.J.; Robinson, C.M.; Torgerson, D.J.; Wallace, W.A.; RECORD Trial Group. Longterm follow-up for mortality and cancer in a randomized placebo-controlled trial of vitamin D3 and/ or calcium (RECORD Trial). J. Clin. Endocrinol. Metab., 2012, 97(2), 614-22
46. Liu, S.; Song, Y.; Ford, E.S.; Manson, J.E.; Buring, J.E.; Ridker, P.M. Dietary calcium, vitamin D, and the prevalence of metabolic syndrome in middle-aged and older U.S. women. Diabetes Care, 2005, 28(12), 2926-32.
47. Jacqueline, S.; Joann, E. Vitamin D and Cardiovascular Disease. Curr. Treat Options Cardiovasc. Med., 2012, 14, 414-424
48. Institute of Medicine. Dietary reference intakes for calcium and vitamin D. Washington: National Academies Press; 2011.
49. Shapses, S.A.; Manson, JE. Vitamin D and prevention of cardiovascular disease and diabetes: why the evidence falls short. JAMA, 2011, 305(24), 2565-6.
50. Forman, J.P.; Bischoff-Ferrari, H.A.; Willett, W.C.; Stampfer, M.J.; Curhan, G.C. Vitamin D intake and risk of incident hypertension results from three large prospective cohort studies. Hypertension, 2005, 46, 676-682.
51. Martins, D.; Wolf, M.; Pan, D.; Zadshir, A.; Tareen, N.; Thadhani, R.; Felsenfeld, A.; Levine, B.; Mehrotra, R.; Norris, K. Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States. Arch Intern. Med., 2007, 167, 1159-1165.
52. Koshiyama, H.; Ogawa, Y.; Tanaka, K.; Tanaka, I. The unified hypothesis of interactions among the bone, adipose and vascularsystems: 'Osteo-lipo-vascular interactions'. Med. Hypotheses., 2006, 66, 960-963.
53. Pilz S.; Tomaschitz A. Vitamin D status and arterial hypertension: a systematic review. Nat. Rev. Cardiol., 2009, 6, 621-630.
54. Kawashima, H. 1,25-Dihydroxyvitamin D3 stimulates Ca-ATPase in a vascular smooth muscle cell line. Biochem. Biophys. Res. Commun., 1988, 150, 1138-1143.
55. Shan J.; Resnick L.M. 1,25-Dihydroxyvitamin D as a cardiovascular hormone. Effects on calcium current and cytosolic free calcium in vascular smooth muscle cells. Am. J. Hypertens., 1993, 6, 983-988.
56. Ishibashi, K.; Bukoski, R.D. Myosin isoform expression and force generation in cultured resistance arteries. Am. J. Physiol., 1997, 272, 1144-1150.
57. Wakasugi, M.; Noguchi, T. Vitamin D stimulates the production of prostacyclin by vascular smooth muscle cells. Prostaglandins, 1991, 42, 127-136.
58. Mitsuhashi, T.; Morris, R.C. 1,25-Dihydroxyvitamin D3 modulates growth of vascular smooth muscle cells. J. Clin. Invest., 1991, 87, 1889-1895.
59. Boonstra, A.; Barrat, F.J.; Crain, C. 1,25-dihydroxyvitamin D3 has a direct effect in na?ve CD4+ cells to enhance the development of Th2 cells. J. Immunol., 2001, 167, 4974-4980.
60. Targher, G.; Bertolini, R.; Padovani, R. Serum 25-hydroxyvitamin D3 concentrations and carotid intima-media thickness among type 2 diabetic patients. Clin. Endocrinol., 2006, 65, 593-597.
61. Reis, J.P.; von Muhlen, D. Serum vitamin D, parathyroid hormone levels, and carotid atherosclerosis. Atherosclerosis, 2009, 207, 585-590.
62. Wang, T.J.; Pencina, M.J.; Booth, S.L. Vitamin D deficiency and risk of cardiovascular disease. Circulation, 2008, 117, 503-511.
63. Li, Y.C.; Kong, J. 1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system. J. Clin. Invest., 2002, 110, 229-238.
64. Mancuso, P.; Rahman, A. 1,25-dihydroxyvitamin-D3 treatment reduces cardiac hypertrophy and left ventricular diameter in spontaneously hypertensive heart failure-prone (cp/+) rats independent of changes in serum leptin. J. Cardiovasc. Pharmacol., 2008, 51, 559-564.
65. Pilz S.; Marz W. Association of vitamin D deficiency with heart failure and sudden cardiac death in a large cross-sectional study of patients referred for coronary angiography. J. Clin. Endocrinol. Metab., 2008, 93, 3924-3935.
66. Witham, M.D.; Crighton, L.J. The effects of vitamin D supplementation on physical function and quality of life in older patients with heart failure: a randomized controlled trial. Circ. Heart. Fail., 2010, 3, 195-201.
67. Zhu, Y., Mahon, B.D. Calcium and 1 alpha, 25-dihydroxyvitamin D3 target the TNF-alpha pathway to suppress experimental inflammatory bowel disease. Eur. J. Immunol., 2005, 35, 217-224.
68. Muray, S.; Parisi, E. Influence of vitamin D receptor gene polymorphisms and 25-hydroxyvitamin D on blood pressure in apparently healthy subjects. J. Hypertens., 2003, 21, 2069-2075.
69. Krause R.; Buhring, M. Ultraviolet B and blood pressure. Lancet, 1998, 352, 709-710.
70. Jorde, R.; Fingschau, Y.; Emaus, N. Serum 25-Hydroxyvitamin D Levels Are Strongly Related to Systolic Blood Pressure But Do Not Predict Future Hypertension. Hypertension, 2010, 55, 792-798.
71. Scragg, R.K.; Camargo, C.A. Relation of serum 25-hydroxyvitamin D to heart rate and cardiac work (from the National Health and Nutrition Examination Surveys). Am. J. Cardiol., 2010, 105, 122-128.
72. Blutt, S.E.; Polek, T.C.; Steward, L.V.; Kattan, M.W.; Weigel, N.L. A calcitriol analogue, EB1089, inhibits the growth of LNCaP tumors in nude mice. Cancer Res.; 2000, 60, 779-782.
73. Brown, A.J. Therapeutic uses of vitamin D analogues. Am. J. Kidney Dis., 2001, 38, S3-S19.
74. Lichtenstein, A.H. Nutrient supplements and cardiovascular disease: a heartbreaking story. J. Lipid Res., 2009, 50, S429-S433.
75. Opolski, A.; Wietrzyk, J.; Chrobak, A.; Marcinkowska, E.; Wojdat, E.; Kutner, A.; Radzikowski, C. Antiproliferative activity in vitro of sidechain analogues of calcitriol against various human normal and cancer cell lines. Anticancer Res., 1999, 19, 5217-5222.
76. Foley, R.N.; Parfrey, P, Harnett, J, Kent, G; Murray, D; Barre, P E. The prognostic importance of left ventricular geometryin uremic cardiomyopathy. J. Am. Soc. Nephrol., 1995, 5, 2024-2031.
77. Foley, R.N.; Parfrey, P.S.; Harnett, J.D.; Kent, G.M.; Murray, D.C.; Barre, P.E. Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease. Kidney Int., 1996, 49, 1379-1385.
78. Tishkoff, D.X.; Nibbelink, K.A.; Holmberg, K.H.; Dandu, L.; Simpson, R.U. Functional vitamin D receptor (VDR) in the ttubules of cardiac myocytes: VDR knockout cardiomyocyte contractility. Endocrinology, 2008, 149, 558-564.
79. O'Connell, T.D.; Berry, J.E.; Jarvis, A.K.; Somerman, M.J.; Simpson, R.U. 1,25-Dihydroxyvitamin D3 regulation of cardiac myocyte proliferation and hypertrophy. Am. J. Physiol. Heart. Circ. Physiol., 1997, 272, H1751-H1758.
80. Ayus J.C.; Mizani M.R.; Achinger S.G.; Thadhani R.; Go A.S.; Lee S.K. Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: a prospective, controlled study. J. Am. Soc. Nephrol., 2005, 16, 2778-2788.
81. Ma, Y.F.; Khalifa, B.; Yee, Y.K.; Lu, J.F.; Memezawa, A.; Savkur, R.S.; Yamamoto, Y.; Chintalacharuvu, S.R.; Yamaoka, K.; Stayrook, K.R.; Bramlett, K.S.; Zeng, Q.Q.; Chandrasekhar, S.; Yu, X.P.; Linebarger, J.H.; Iturria, S.J.; Burris, T.P.; Kato, S.; Chin, W.W.; Nagpal, S. Identification and characterization of noncalcemic, tissue-selective, nonsecosteroidal vitamin D receptor modulators. J. Clin. Invest., 2006, 116, 892-904.
82. Fryer, R.M.; Rakestraw, P.A.; Nakane, M.; Dixon, D.; Banfor, P.N.; Koch, K.A.; Wu-Wong, J.R.; Reinhart, G.A. Differential inhibition of renin mRNA expression by paricalcitol and calcitriol in C57/BL6 mice. Nephron. Physiol., 2007, 106, 76-81.
83. Cardus, A.; Panizo S.; Encinas, M.; Dolcet, X.; Gallego, C.; Aldea, M.; Fernandez, E.; Valdivielso, J.M. 1,25-Dihydroxyvitamin D3 regulates VEGF production through a vitamin D response element in the VEGF promoter. Atherosclerosis, 2009, 204, 85-89.
84. Cardus, A.; Panizo, S.; Parisi, E.; Fernandez, E.; Valdivielso, J.M. Differential effects of vitamin D analogues on vascular calcification. J. Bone. Miner. Res., 2007, 22, 860-866.
85. Mizobuchi, M.; Finch, J.L.; Martin, D.R.; Slatopolsky E. Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. Kidney Int., 2007, 72, 709-715.
86. Timms, P.M.; Mannan, N.; Hitman, G.A.; Noonan, K.; Mills, P.G.; Syndercombe-Court Aganna E.; Price C.P.; Boucher B.J. Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: mechanisms for inflammatory damage in chronic disorders? QJM., 2002, 95, 787-796.
87. Sun, Q.; Shi, L.; Rimm, E.B.; Giovannucci, E.L.; Hu, F.B.; Manson, J.E.; Rexrode, K.M. Vitamin D intake and risk of cardiovascular disease in US men and women. Am J Clin Nutr., 2011, 94, 534-42.
88. Vacek, J.L.; Vanga, S.R.; Good, M.; Lai, S.M.; Lakkireddy, D.; Howard, PA. Vitamin D deficiency and supplementation and relation to cardiovascular health. Am. J. Cardiol., 2012, 109, 359-63.
89. Manson JE.; Allison MA.; Carr JJ. et al. Calcium/vitamin D supplementation and coronary artery calcification in the Women's Health Initiative. Menopause. 2010, 17, 683-91.
90. Hsia, J.; Heiss, G.; Ren, H.; Allison, M.; Dolan, N.C.; Greenland, P.; Heckbert, S.R.; Johnson, K.C.; Manson, J.E.; Sidney, S.; Trevisan, M. Women's Health Initiative Investigators. Calcium/ vitamin D supplementation and cardiovascular events. Circulation, 2007, 115, 846-54
91. LaCroix, A.Z.; Kotchen, J.; Anderson, G.; Brzyski, R.; Cauley, J.A.; Cummings, S.R.; Gass, M.; Johnson, K.C.; Ko, M.; Larson, J.; Manson, J.E.; Stefanick, M.L.; Wactawski-Wende, J. Calcium plus vitamin D supplementation and mortality in postmenopausal women: the Women's Health Initiative calcium-vitamin D randomized controlled trial. J. Gerontol. A. Biol. Sci. Med. Sci., 2009, 64, 559-67.
92. Van der Schueren, B.J.; Verstuyf, A.; Mathieu C. Straight from DHeart: vitamin D status and cardiovascular disease. Curr Opin Lipidol., 2012, 23, 17-23.
93. Manson, J.E.; Bassuk, S.S.; Lee, I.M.; Cook, N.R.; Albert, M.A.; Gordon, D.; Zaharris, E.; Macfadyen, J.G.; Danielson, E.; Lin, J.; Zhang, S.M.; Buring, J.E. The VITamin D and OmegA-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements forthe primary prevention of cancer and cardiovascular disease. Contemp Clin Trials., 2012, 33(1), 159-71.
94. Lewis, J.R.; Calver, J.; Zhu, K.; Flicker, L.; Prince, R.L. Calcium supplementation and the risks of atherosclerotic vascular disease in older women: results of a 5-year RCT and a 4.5-year follow-up. J. Bone Miner. Res., 2011, 26, 35-41.
95. Reid, I.R.; Bolland, M.J.; Grey, A. Does calcium supplementation increase cardiovascular risk? Clin. Endocrinol., 2010, 73, 689-69.
96. Reid, I.R.; Bolland, M.J.; Avenell, A.; Grey, A. Cardiovascular effects of calcium supplementation Osteoporos Int., 2011, 22, 1649-1658.